{"id":19069,"date":"2024-12-20T16:53:05","date_gmt":"2024-12-20T08:53:05","guid":{"rendered":"https:\/\/flcube.com\/?p=19069"},"modified":"2024-12-20T16:53:08","modified_gmt":"2024-12-20T08:53:08","slug":"astellas-pharma-inks-licensing-deal-with-sangamo-therapeutics-for-neurological-av-capsid-stac-bbb","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19069","title":{"rendered":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB"},"content":{"rendered":"\n

Japan-based Astellas Pharma Inc. (TYO: 4503<\/a>) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO<\/a>). This collaboration will enable Astellas to utilize Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.<\/p>\n\n\n\n

Financial Terms and Potential Impact on Astellas’ Pipeline<\/strong>
The agreement allows Astellas to expand its pipeline with up to four additional targets after paying additional licensed target fees. In return, Sangamo will receive an upfront payment of USD 20 million from the five potential programs. The company is also eligible to receive an aggregate of up to USD 1.3 billion in license fees and milestone payments, highlighting the significant potential value of the collaboration.<\/p>\n\n\n\n

Implications for Neurological Treatment and the Pharmaceutical Sector<\/strong>
The partnership between Astellas Pharma and Sangamo Therapeutics signifies a significant step forward in the development of innovative neurological treatments. By leveraging Sangamo’s proprietary technology, Astellas is poised to enhance its offerings in the neurological therapeutic space, potentially leading to new treatment options for patients and contributing to the growth of the pharmaceutical sector.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo…<\/p>\n","protected":false},"author":1,"featured_media":19070,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[353,66,2856,412,1177],"class_list":["post-19069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-astellas-pharma","tag-gene-therapy","tag-nasdaq-sgmo","tag-sangamo-therapeutics","tag-tyo-4503"],"yoast_head":"\nAstellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19069\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB\" \/>\n<meta property=\"og:description\" content=\"Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19069\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T08:53:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-20T08:53:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"499\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB\",\"datePublished\":\"2024-12-20T08:53:05+00:00\",\"dateModified\":\"2024-12-20T08:53:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069\"},\"wordCount\":192,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2013.png\",\"keywords\":[\"Astellas Pharma\",\"Gene therapy\",\"NASDAQ: SGMO\",\"Sangamo Therapeutics\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19069#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19069\",\"name\":\"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2013.png\",\"datePublished\":\"2024-12-20T08:53:05+00:00\",\"dateModified\":\"2024-12-20T08:53:08+00:00\",\"description\":\"Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19069\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2013.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2013.png\",\"width\":1080,\"height\":499,\"caption\":\"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19069#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB - Insight, China's Pharmaceutical Industry","description":"Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19069","og_locale":"en_US","og_type":"article","og_title":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB","og_description":"Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.","og_url":"https:\/\/flcube.com\/?p=19069","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-20T08:53:05+00:00","article_modified_time":"2024-12-20T08:53:08+00:00","og_image":[{"width":1080,"height":499,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19069#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19069"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB","datePublished":"2024-12-20T08:53:05+00:00","dateModified":"2024-12-20T08:53:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19069"},"wordCount":192,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19069#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png","keywords":["Astellas Pharma","Gene therapy","NASDAQ: SGMO","Sangamo Therapeutics","TYO: 4503"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19069#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19069","url":"https:\/\/flcube.com\/?p=19069","name":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19069#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19069#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png","datePublished":"2024-12-20T08:53:05+00:00","dateModified":"2024-12-20T08:53:08+00:00","description":"Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo Therapeutics, Inc. (NASDAQ: SGMO). This collaboration will enable Astellas to utilize Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, targeting an undisclosed neurological condition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19069#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19069"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19069#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png","width":1080,"height":499,"caption":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19069#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2013.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19069"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19069\/revisions"}],"predecessor-version":[{"id":19071,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19069\/revisions\/19071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19070"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}